What does this research mean for the field?

SGLT2 inhibitors reduce the risk of arrhythmias by mitigating cardiac electrical and structural remodeling through the regulation of ion homeostasis, fibrosis, inflammation, oxidative stress, and apoptosis. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 20, 2022Frontiers in Cardiovascular MedicineOpen Access

Benefits of SGLT2 inhibitors in arrhythmias

View Full Paper

Ask AI

Bookmark

Why the study?

Emerging research shows SGLT2 inhibitors can reduce the risk of arrhythmias, prompting an exploration of the underlying electrical and structural remodeling mechanisms.

Do SGLT2 inhibitors reduce the risk of arrhythmias through electrical and structural remodeling?

Structured PICO

Do SGLT2 inhibitors reduce the risk of arrhythmias through electrical and structural remodeling?

Population

Patients with cardiovascular diseases such as heart failure, dilated cardiomyopathy, and myocardial infarction, or at risk of arrhythmias

Intervention

SGLT2 inhibitors

Outcome

Reduction in the risk of arrhythmia

This review highlights the potential mechanisms by which SGLT2 inhibitors may reduce the risk of arrhythmias, including modulation of ion homeostasis and attenuation of structural remodeling.

Implication

Supports mechanistic rationale for SGLT2i arrhythmia prevention; leaves open clinical efficacy pending randomized data.

Abstract

Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. With the development of research, SGLT2 inhibitors can also reduce the risk of arrhythmias. So in this review, how SGLT2 inhibitors play a role in reducing the risk of arrhythmia from the perspective of electrical remodeling and structural remodeling are explored and then the possible mechanisms are discussed. Specifically, we focus on the role of SGLT2 inhibitors in Na + and Ca 2 + homeostasis and the transients of Na + and Ca 2 + , which could affect electrical remodeling and then lead to arrythmia. We also discuss the protective role of SGLT2 inhibitors in structural remodeling from the perspective of fibrosis, inflammation, oxidative stress, and apoptosis. Ultimately, it is clear that SGLT2 inhibitors have significant benefits on cardiovascular diseases such as HF, myocardial hypertrophy and myocardial infarction. It can be expected that SGLT2 inhibitors can reduce the risk of arrhythmia.